Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference

Fireside Chat with Management on Tuesday, November 11, 2025, at 3:20 p.m. ET

NEW HAVEN, Conn., Nov. 4, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and James Cassella, Ph.D., Chief Development Officer, will participate in a fireside chat at the Stifel 2025 Healthcare Conference on Tuesday, November 11, at 3:20 p.m. ET. Held from November 11-12 in New York, Ms. Good and Dr. Cassella will also participate in investor meetings with attendees at the event. This fireside chat and meetings will be available for in-person attendees.

Read more at prnewswire.com